Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

An Indian court has allowed Dr. Reddy’s Laboratories Ltd. to manufacture and export generic versions of Novo Nordisk A/S’s ...

Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming ...

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment analysis.

Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...